Upgrade to BuyandBill.com Pro to access this report and the complete suite of analytics tools.
| Manufacturer ▼ | Drug Name | Indication | Stage | Status | Route of Administration | Drug Class |
|---|---|---|---|---|---|---|
| AC Immune SA | ACI-7104.056 - (VacSYn) | Parkinson's disease (PD) | Phase 2 | Data Released | Intramuscular | Neurology |
| AC Immune SA | ACI-24 | Alzheimer’s disease (AD) | Phase 2 | Trial Completed | Subcutaneous | Neurology |
| AC Immune SA | Semorinemab - (LAURIET) | Alzheimer’s disease (AD) | Phase 2 | Data Released | Intravenous | Neurology |
| AC Immune SA | Semorinemab | Alzheimer’s disease | Phase 2 | Trial Discontinued | Intravenous | Neurology |
| ACADIA Pharmaceuticals Inc. | Trofinetide - (Japan study) | Rett syndrome | Phase 3 | Ongoing | Oral | Genetic Disorder |
| ACADIA Pharmaceuticals Inc. | NUPLAZID (pimavanserin) - (Advance-2) | Adjunctive treatment in patients with negative symptoms of schizophrenia | Phase 3 | Trial Discontinued | Oral | Psychiatric |
| ACADIA Pharmaceuticals Inc. | NUPLAZID (pimavanserin) CLARITY-2 and CLARITY-3 | Adjunctive Treatment in Patients With Major Depressive Disorder | Phase 3 | Trial Discontinued | Oral | Psychiatric |
| ACADIA Pharmaceuticals Inc. | Carbetocin (ACP-101) - (COMPASS PWS) | Prader-Willi syndrome (PWS) | Phase 3 | Data Released | Intravenous | Genetic Disorder |
